Breaking News

Thursday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Aurinia Pharmaceuticals management to meet virtually with Cantor Fitzgerald » 17:01
07/09/20
07/09
17:01
07/09/20
17:01
AUPH

Aurinia Pharmaceuticals

$15.24 /

-0.35 (-2.25%)

Virtual Meeting to be…

Virtual Meeting to be held on July 13 hosted by Cantor Fitzgerald.

ShowHide Related Items >><<
AUPH Aurinia Pharmaceuticals
$15.24 /

-0.35 (-2.25%)

AUPH Aurinia Pharmaceuticals
$15.24 /

-0.35 (-2.25%)

06/16/20 BTIG
Aurinia Pharmaceuticals initiated with a Buy at BTIG
05/05/20 Cowen
Aurinia Pharmaceuticals initiated with an Outperform at Cowen
03/16/20 H.C. Wainwright
Aurinia's voclosporin could get FDA approval in 1Q21, says H.C. Wainwright
01/10/20 Jefferies
Aurinia Pharmaceuticals initiated with a Buy at Jefferies
AUPH Aurinia Pharmaceuticals
$15.24 /

-0.35 (-2.25%)

  • 10
    Dec
AUPH Aurinia Pharmaceuticals
$15.24 /

-0.35 (-2.25%)

AUPH Aurinia Pharmaceuticals
$15.24 /

-0.35 (-2.25%)

Conference/Events
Aurinia Pharmaceuticals participates in a conference call with Cowen » 17:00
07/09/20
07/09
17:00
07/09/20
17:00
AUPH

Aurinia Pharmaceuticals

$15.24 /

-0.35 (-2.25%)

Pharmaceutical Analyst…

Pharmaceutical Analyst Cacciatore holds a conference call with management on July 16 at 11 am hosted by Cowen.

ShowHide Related Items >><<
AUPH Aurinia Pharmaceuticals
$15.24 /

-0.35 (-2.25%)

AUPH Aurinia Pharmaceuticals
$15.24 /

-0.35 (-2.25%)

06/16/20 BTIG
Aurinia Pharmaceuticals initiated with a Buy at BTIG
05/05/20 Cowen
Aurinia Pharmaceuticals initiated with an Outperform at Cowen
03/16/20 H.C. Wainwright
Aurinia's voclosporin could get FDA approval in 1Q21, says H.C. Wainwright
01/10/20 Jefferies
Aurinia Pharmaceuticals initiated with a Buy at Jefferies
AUPH Aurinia Pharmaceuticals
$15.24 /

-0.35 (-2.25%)

  • 10
    Dec
AUPH Aurinia Pharmaceuticals
$15.24 /

-0.35 (-2.25%)

AUPH Aurinia Pharmaceuticals
$15.24 /

-0.35 (-2.25%)

Over a week ago
Hot Stocks
Aurinia Pharmaceuticals completes enrollment in Phase 2/3 AUDREY trial » 06:16
06/22/20
06/22
06:16
06/22/20
06:16
AUPH

Aurinia Pharmaceuticals

$16.70 /

+0.2 (+1.21%)

Aurinia Pharmaceuticals…

Aurinia Pharmaceuticals announced it has completed enrollment for the Phase 2/3 AUDREY clinical trial evaluating voclosporin ophthalmic solution for the potential treatment of dry eye syndrome, a chronic disease estimated to affect more than 16M people in the United States.

ShowHide Related Items >><<
AUPH Aurinia Pharmaceuticals
$16.70 /

+0.2 (+1.21%)

AUPH Aurinia Pharmaceuticals
$16.70 /

+0.2 (+1.21%)

06/16/20 BTIG
Aurinia Pharmaceuticals initiated with a Buy at BTIG
05/05/20 Cowen
Aurinia Pharmaceuticals initiated with an Outperform at Cowen
03/16/20 H.C. Wainwright
Aurinia's voclosporin could get FDA approval in 1Q21, says H.C. Wainwright
01/10/20 Jefferies
Aurinia Pharmaceuticals initiated with a Buy at Jefferies
AUPH Aurinia Pharmaceuticals
$16.70 /

+0.2 (+1.21%)

AUPH Aurinia Pharmaceuticals
$16.70 /

+0.2 (+1.21%)

AUPH Aurinia Pharmaceuticals
$16.70 /

+0.2 (+1.21%)

AUPH Aurinia Pharmaceuticals
$16.70 /

+0.2 (+1.21%)

Initiation
Aurinia Pharmaceuticals initiated with a Buy at BTIG » 19:33
06/16/20
06/16
19:33
06/16/20
19:33
AUPH

Aurinia Pharmaceuticals

$15.92 /

-0.39 (-2.39%)

BTIG analyst Dae Gon Ha…

BTIG analyst Dae Gon Ha initiated coverage of Aurinia Pharmaceuticals with a Buy rating and $20 price target. The analyst cites positive topline results from Phase 3 AURORA lupus nephritis, or LN, study that "pushed voclosporin one-step closer to commercialization", adding that limited competition in LN, attractive safety/efficacy profile of voclosporin, and the dry eye syndrome opportunity warrant a positive view on the stock.

ShowHide Related Items >><<
AUPH Aurinia Pharmaceuticals
$15.92 /

-0.39 (-2.39%)

AUPH Aurinia Pharmaceuticals
$15.92 /

-0.39 (-2.39%)

05/05/20 Cowen
Aurinia Pharmaceuticals initiated with an Outperform at Cowen
03/16/20 H.C. Wainwright
Aurinia's voclosporin could get FDA approval in 1Q21, says H.C. Wainwright
01/10/20 Jefferies
Aurinia Pharmaceuticals initiated with a Buy at Jefferies
12/16/19 H.C. Wainwright
Aurinia Pharmaceuticals price target raised to $32 from $25 at H.C. Wainwright
AUPH Aurinia Pharmaceuticals
$15.92 /

-0.39 (-2.39%)

AUPH Aurinia Pharmaceuticals
$15.92 /

-0.39 (-2.39%)

AUPH Aurinia Pharmaceuticals
$15.92 /

-0.39 (-2.39%)

AUPH Aurinia Pharmaceuticals
$15.92 /

-0.39 (-2.39%)

Over a month ago
Hot Stocks
Aurinia Pharmaceuticals presents additional AURORA trial safety data » 06:08
06/09/20
06/09
06:08
06/09/20
06:08
AUPH

Aurinia Pharmaceuticals

$15.62 /

+0.66 (+4.41%)

Aurinia Pharmaceuticals…

Aurinia Pharmaceuticals announced that additional safety data from the completed AURORA pivotal trial of voclosporin were shared at the European Renal Association-European Dialysis and Transplant Association 2020 Virtual Congress in an oral presentation given by nephrologist Dawn Caster, M.D., Assistant Professor of Medicine at the University of Louisville School of Medicine. The data showed that pre-specified confirmed estimated glomerular filtration rate decreases of over 30% were similar in both AURORA trial patient groups, with 10.1% reported in the voclosporin group and 10.2% in the control arm. eGFR is a standard measure of kidney function. No clinically meaningful differences between the treatment and control groups were seen at any timepoints in the study on this parameter or in serum creatinine levels, another biomarker for renal damage. All patients in the AURORA study were treated with mycophenolate and a background of corticosteroids. MMF is considered the standard-of-care for lupus nephritis, although unapproved by the FDA for that use.

ShowHide Related Items >><<
AUPH Aurinia Pharmaceuticals
$15.62 /

+0.66 (+4.41%)

AUPH Aurinia Pharmaceuticals
$15.62 /

+0.66 (+4.41%)

05/05/20 Cowen
Aurinia Pharmaceuticals initiated with an Outperform at Cowen
03/16/20 H.C. Wainwright
Aurinia's voclosporin could get FDA approval in 1Q21, says H.C. Wainwright
01/10/20 Jefferies
Aurinia Pharmaceuticals initiated with a Buy at Jefferies
12/16/19 H.C. Wainwright
Aurinia Pharmaceuticals price target raised to $32 from $25 at H.C. Wainwright
AUPH Aurinia Pharmaceuticals
$15.62 /

+0.66 (+4.41%)

AUPH Aurinia Pharmaceuticals
$15.62 /

+0.66 (+4.41%)

AUPH Aurinia Pharmaceuticals
$15.62 /

+0.66 (+4.41%)

AUPH Aurinia Pharmaceuticals
$15.62 /

+0.66 (+4.41%)

Hot Stocks
Aurinia Pharmaceuticals presents new subgroup analyses from AURORA trial » 07:16
06/05/20
06/05
07:16
06/05/20
07:16
AUPH

Aurinia Pharmaceuticals

$15.09 /

+0.08 (+0.53%)

Aurinia Pharmaceuticals…

Aurinia Pharmaceuticals announced that new subgroup analyses from the completed AURORA pivotal trial of voclosporin were presented. The data were shared at the European League Against Rheumatism, or EULAR, 2020 E-Congress in an oral presentation. The presented data demonstrated clinically meaningful benefits of voclosporin for trial participants across ethnicities and self-reported race. Significant renal response rates were seen for Hispanic/Latino patients in the voclosporin arm versus control arm, as well as for non-Hispanic/Latino patients in the voclosporin arm versus the control arm. Furthermore, all other pre-specified subgroup analyses favored voclosporin.

ShowHide Related Items >><<
AUPH Aurinia Pharmaceuticals
$15.09 /

+0.08 (+0.53%)

AUPH Aurinia Pharmaceuticals
$15.09 /

+0.08 (+0.53%)

05/05/20 Cowen
Aurinia Pharmaceuticals initiated with an Outperform at Cowen
03/16/20 H.C. Wainwright
Aurinia's voclosporin could get FDA approval in 1Q21, says H.C. Wainwright
01/10/20 Jefferies
Aurinia Pharmaceuticals initiated with a Buy at Jefferies
12/16/19 H.C. Wainwright
Aurinia Pharmaceuticals price target raised to $32 from $25 at H.C. Wainwright
AUPH Aurinia Pharmaceuticals
$15.09 /

+0.08 (+0.53%)

AUPH Aurinia Pharmaceuticals
$15.09 /

+0.08 (+0.53%)

AUPH Aurinia Pharmaceuticals
$15.09 /

+0.08 (+0.53%)

AUPH Aurinia Pharmaceuticals
$15.09 /

+0.08 (+0.53%)

Syndicate
Aurinia Pharmaceuticals files $500M mixed securities shelf  16:10
05/29/20
05/29
16:10
05/29/20
16:10
AUPH

Aurinia Pharmaceuticals

$15.79 /

+0.43 (+2.80%)

 
ShowHide Related Items >><<
AUPH Aurinia Pharmaceuticals
$15.79 /

+0.43 (+2.80%)

AUPH Aurinia Pharmaceuticals
$15.79 /

+0.43 (+2.80%)

05/05/20 Cowen
Aurinia Pharmaceuticals initiated with an Outperform at Cowen
03/16/20 H.C. Wainwright
Aurinia's voclosporin could get FDA approval in 1Q21, says H.C. Wainwright
01/10/20 Jefferies
Aurinia Pharmaceuticals initiated with a Buy at Jefferies
12/16/19 H.C. Wainwright
Aurinia Pharmaceuticals price target raised to $32 from $25 at H.C. Wainwright
AUPH Aurinia Pharmaceuticals
$15.79 /

+0.43 (+2.80%)

AUPH Aurinia Pharmaceuticals
$15.79 /

+0.43 (+2.80%)

AUPH Aurinia Pharmaceuticals
$15.79 /

+0.43 (+2.80%)

AUPH Aurinia Pharmaceuticals
$15.79 /

+0.43 (+2.80%)

Hot Stocks
Aurinia Pharmaceuticals completes submission of NDA to FDA for voclosporin » 06:06
05/26/20
05/26
06:06
05/26/20
06:06
AUPH

Aurinia Pharmaceuticals

$16.22 /

-0.44 (-2.64%)

Aurinia Pharmaceuticals…

Aurinia Pharmaceuticals announced the completion of the rolling submission of a New Drug Application to the United States FDA for voclosporin as a potential treatment for lupus nephritis, a serious inflammation of the kidneys caused by the autoimmune disease systemic lupus erythematosus. There are currently no FDA-approved treatments for LN. The NDA submission includes a request for Priority Review, which, if granted, would shorten the FDA's review of the NDA to eight months from the time of submission, versus a standard review timeline of 12 months.

ShowHide Related Items >><<
AUPH Aurinia Pharmaceuticals
$16.22 /

-0.44 (-2.64%)

AUPH Aurinia Pharmaceuticals
$16.22 /

-0.44 (-2.64%)

05/05/20 Cowen
Aurinia Pharmaceuticals initiated with an Outperform at Cowen
03/16/20 H.C. Wainwright
Aurinia's voclosporin could get FDA approval in 1Q21, says H.C. Wainwright
01/10/20 Jefferies
Aurinia Pharmaceuticals initiated with a Buy at Jefferies
12/16/19 H.C. Wainwright
Aurinia Pharmaceuticals price target raised to $32 from $25 at H.C. Wainwright
AUPH Aurinia Pharmaceuticals
$16.22 /

-0.44 (-2.64%)

AUPH Aurinia Pharmaceuticals
$16.22 /

-0.44 (-2.64%)

AUPH Aurinia Pharmaceuticals
$16.22 /

-0.44 (-2.64%)

AUPH Aurinia Pharmaceuticals
$16.22 /

-0.44 (-2.64%)

On The Fly
Fly Intel: After-Hours Movers » 19:11
05/14/20
05/14
19:11
05/14/20
19:11
YTEN

Yield10 Bioscience

$4.92 /

-0.02 (-0.40%)

, OPRT

Oportun Financial

$6.00 /

-0.25 (-4.00%)

, DENN

Denny's

$8.77 /

-0.035 (-0.40%)

, ACB

Aurora Cannabis

$6.61 /

+0.79 (+13.57%)

, AEYE

AudioEye

$8.88 /

+0.71 (+8.69%)

, NEWR

New Relic

$58.22 /

+1.62 (+2.86%)

, DDS

Dillard's

$22.94 /

-1.15 (-4.77%)

, AMAT

Applied Materials

$54.51 /

+2.98 (+5.78%)

, GLOB

Globant

$111.38 /

+3.1 (+2.86%)

, OCUL

Ocular Therapeutix

$6.01 /

-0.3 (-4.75%)

, REGN

Regeneron

$569.80 /

-7.58 (-1.31%)

, CODX

Co-Diagnostics

$22.19 /

-1.2 (-5.13%)

, FTCH

Farfetch

$15.94 /

+0.35 (+2.25%)

, CVET

Covetrus

$11.25 /

+0.3 (+2.74%)

, ETON

Eton Pharmaceuticals

$5.20 /

+0.03 (+0.58%)

, AUPH

Aurinia Pharmaceuticals

$17.39 /

-0.19 (-1.08%)

, VVI

Viad

$16.65 /

+0.71 (+4.45%)

, TGTX

TG Therapeutics

$19.90 /

-0.72 (-3.49%)

Check out this evening's…

Open Full Text

ShowHide Related Items >><<
YTEN Yield10 Bioscience
$4.92 /

-0.02 (-0.40%)

VVI Viad
$16.65 /

+0.71 (+4.45%)

TGTX TG Therapeutics
$19.90 /

-0.72 (-3.49%)

REGN Regeneron
$569.80 /

-7.58 (-1.31%)

OPRT Oportun Financial
$6.00 /

-0.25 (-4.00%)

OCUL Ocular Therapeutix
$6.01 /

-0.3 (-4.75%)

NEWR New Relic
$58.22 /

+1.62 (+2.86%)

GLOB Globant
$111.38 /

+3.1 (+2.86%)

FTCH Farfetch
$15.94 /

+0.35 (+2.25%)

ETON Eton Pharmaceuticals
$5.20 /

+0.03 (+0.58%)

DENN Denny's
$8.77 /

-0.035 (-0.40%)

DDS Dillard's
$22.94 /

-1.15 (-4.77%)

CVET Covetrus
$11.25 /

+0.3 (+2.74%)

CODX Co-Diagnostics
$22.19 /

-1.2 (-5.13%)

AUPH Aurinia Pharmaceuticals
$17.39 /

-0.19 (-1.08%)

AMAT Applied Materials
$54.51 /

+2.98 (+5.78%)

AEYE AudioEye
$8.88 /

+0.71 (+8.69%)

ACB Aurora Cannabis
$6.61 /

+0.79 (+13.57%)

YTEN Yield10 Bioscience
$4.92 /

-0.02 (-0.40%)

12/11/19 Ladenburg
Yield10 Bioscience price target lowered to $1 from $7 at Ladenburg
11/18/19 National Securities
Yield10 Bioscience downgraded to Neutral from Buy at National Securities
07/22/19 Aegis
Yield10 Bioscience initiated with a Buy at Aegis
OPRT Oportun Financial
$6.00 /

-0.25 (-4.00%)

04/07/20 BTIG
Oportun Financial price target lowered to $19 from $27 at BTIG
01/17/20 JPMorgan
Oportun Financial downgraded to Neutral on valuation at JPMorgan
01/17/20 JPMorgan
Oportun Financial downgraded to Neutral from Overweight at JPMorgan
12/23/19 BTIG
Oportun Financial price target raised to $27 from $22 at BTIG
DENN Denny's
$8.77 /

-0.035 (-0.40%)

04/08/20 Oppenheimer
Denny's price target lowered to $13 from $27 at Oppenheimer
04/01/20 SunTrust
El Pollo Loco upgraded to Buy from Hold at SunTrust
04/01/20 SunTrust
Denny's upgraded to Buy from Hold at SunTrust
03/20/20 Stephens
Denny's price target lowered to $12 from $19 at Stephens
ACB Aurora Cannabis
$6.61 /

+0.79 (+13.57%)

05/13/20 Cantor Fitzgerald
Aurora Cannabis price target raised to C$22 from C$2.75 at Cantor Fitzgerald
04/08/20 Raymond James
Ontario AG order positive for Canadian cannabis stocks, says Raymond James
02/27/20 Bryan Garnier
Aurora Cannabis downgraded to Sell from Neutral at Bryan Garnier
02/25/20 Needham
Aurora Cannabis initiated with a Hold at Needham
AEYE AudioEye
$8.88 /

+0.71 (+8.69%)

10/24/19 National Securities
AudioEye resumed with a Buy at National Securities
05/31/19 B. Riley FBR
AudioEye selloff brings 'compelling' entry point, syays B. Riley FBR
NEWR New Relic
$58.22 /

+1.62 (+2.86%)

04/27/20 Needham
New Relic price target lowered to $74 from $108 at Needham
04/14/20 Morgan Stanley
New Relic downgraded to Equal Weight amid weaker backdrop at Morgan Stanley
04/14/20 Morgan Stanley
New Relic downgraded to Equal Weight from Overweight at Morgan Stanley
04/06/20 Rosenblatt
New Relic initiated with a Neutral at Rosenblatt
DDS Dillard's
$22.94 /

-1.15 (-4.77%)

05/07/20 Deutsche Bank
Dillard's price target lowered to $18 from $36 at Deutsche Bank
04/30/20 Wedbush
Dillard's price target lowered to $25 from $63 at Wedbush
01/24/20 Odeon Capital
Dillard's initiated with a Sell at Odeon Capital
11/11/19 Deutsche Bank
L Brands downgraded to Hold from Buy at Deutsche Bank
AMAT Applied Materials
$54.51 /

+2.98 (+5.78%)

05/12/20 Susquehanna
Applied Materials fundamentals strong ahead of results, says Susquehanna
05/11/20 Cowen
Applied Materials sales trajectory has positive slope, says Cowen
05/08/20 Wells Fargo
Applied Materials price target raised to $60 from $50 at Wells Fargo
04/14/20 Deutsche Bank
Applied Materials share underperformance unwarranted, says Deutsche Bank
GLOB Globant
$111.38 /

+3.1 (+2.86%)

04/29/20 Goldman Sachs
Globant price target lowered to $130 from $165 at Goldman Sachs
04/16/20 Wedbush
Globant price target lowered to $120 from $150 at Wedbush
03/10/20 KeyBanc
Globant downgraded to Sector Weight from Overweight at KeyBanc
02/21/20 Cantor Fitzgerald
Globant price target raised to $120 from $97 at Cantor Fitzgerald
OCUL Ocular Therapeutix
$6.01 /

-0.3 (-4.75%)

05/08/20 Piper Sandler
Ocular Therapeutix long-term opportunity intact, says Piper Sandler
04/29/20 H.C. Wainwright
Ocular Therapeutix price target raised to $10 from $8 at H.C. Wainwright
04/28/20 Piper Sandler
Ocular Therapeutix data warrant discussions with FDA, says Piper Sandler
03/04/20 Piper Sandler
Ocular Therapeutix price target raised to $11 from $7 at Piper Sandler
REGN Regeneron
$569.80 /

-7.58 (-1.31%)

05/14/20 Piper Sandler
Piper 'incrementally positive' on Regeneron shares after fireside chat
05/06/20 Canaccord
Regeneron price target raised to $630 from $575 at Canaccord
05/06/20 BMO Capital
Regeneron price target raised to $525 from $466 at BMO Capital
05/06/20 SVB Leerink
Regeneron price target raised to $622 from $604 at SVB Leerink
CODX Co-Diagnostics
$22.19 /

-1.2 (-5.13%)

03/09/20 H.C. Wainwright
Co-Diagnostics price target raised to $20 from $4 at H.C. Wainwright
03/03/20
Fly Intel: Top five analyst downgrades
03/03/20 Maxim
Co-Diagnostics downgraded to Hold from Buy at Maxim
03/03/20 Maxim
Co-Diagnostics downgraded to Hold from Buy at Maxim
FTCH Farfetch
$15.94 /

+0.35 (+2.25%)

05/14/20 KeyBanc
Farfetch, Nordstrom, Revolve could be impacted by Amazon offering, says KeyBanc
03/30/20 Wells Fargo
Farfetch downgraded to Underweight from Equal Weight at Wells Fargo
02/28/20 KeyBanc
Farfetch price target lowered to $17 from $20 at KeyBanc
11/15/19 Credit Suisse
Farfetch price target lowered to $17 from $22 at Credit Suisse
CVET Covetrus
$11.25 /

+0.3 (+2.74%)

09/09/19 Goldman Sachs
Covetrus initiated with a Sell at Goldman Sachs
08/14/19 Stifel
Covetrus price target lowered to $18 from $30 at Stifel
08/14/19 William Blair
Covetrus risk/reward 'intriguing' after selloff, says William Blair
05/23/19 Guggenheim
Covetrus initiated with a Neutral at Guggenheim
ETON Eton Pharmaceuticals
$5.20 /

+0.03 (+0.58%)

03/30/20 H.C. Wainwright
Eton Pharmaceuticals price target raised to $26 from $23 at H.C. Wainwright
01/28/20 H.C. Wainwright
Eton Pharmaceuticals price target raised to $23 from $21 at H.C. Wainwright
10/23/19 H.C. Wainwright
Eton Pharmaceuticals price target raised to $21 from $18 at H.C. Wainwright
09/20/19
Fly Intel: Top five analyst initiations
AUPH Aurinia Pharmaceuticals
$17.39 /

-0.19 (-1.08%)

05/05/20 Cowen
Aurinia Pharmaceuticals initiated with an Outperform at Cowen
03/16/20 H.C. Wainwright
Aurinia's voclosporin could get FDA approval in 1Q21, says H.C. Wainwright
01/10/20 Jefferies
Aurinia Pharmaceuticals initiated with a Buy at Jefferies
12/16/19 H.C. Wainwright
Aurinia Pharmaceuticals price target raised to $32 from $25 at H.C. Wainwright
VVI Viad
$16.65 /

+0.71 (+4.45%)

TGTX TG Therapeutics
$19.90 /

-0.72 (-3.49%)

05/06/20 Cantor Fitzgerald
TG Therapeutics price target raised to $35 from $19 at Cantor Fitzgerald
05/05/20 B. Riley FBR
TG Therapeutics price target raised to $29 from $25 at B. Riley FBR
05/05/20 H.C. Wainwright
TG Therapeutics price target raised to $32 from $24 at H.C. Wainwright
01/17/20 B. Riley FBR
TG Therapeutics price target raised to $25 from $17 at B. Riley FBR
YTEN Yield10 Bioscience
$4.92 /

-0.02 (-0.40%)

VVI Viad
$16.65 /

+0.71 (+4.45%)

TGTX TG Therapeutics
$19.90 /

-0.72 (-3.49%)

REGN Regeneron
$569.80 /

-7.58 (-1.31%)

OPRT Oportun Financial
$6.00 /

-0.25 (-4.00%)

OCUL Ocular Therapeutix
$6.01 /

-0.3 (-4.75%)

NEWR New Relic
$58.22 /

+1.62 (+2.86%)

GLOB Globant
$111.38 /

+3.1 (+2.86%)

FTCH Farfetch
$15.94 /

+0.35 (+2.25%)

ETON Eton Pharmaceuticals
$5.20 /

+0.03 (+0.58%)

DENN Denny's
$8.77 /

-0.035 (-0.40%)

DDS Dillard's
$22.94 /

-1.15 (-4.77%)

CVET Covetrus
$11.25 /

+0.3 (+2.74%)

CODX Co-Diagnostics
$22.19 /

-1.2 (-5.13%)

AUPH Aurinia Pharmaceuticals
$17.39 /

-0.19 (-1.08%)

AMAT Applied Materials
$54.51 /

+2.98 (+5.78%)

AEYE AudioEye
$8.88 /

+0.71 (+8.69%)

ACB Aurora Cannabis
$6.61 /

+0.79 (+13.57%)

  • 15
    May
REGN Regeneron
$569.80 /

-7.58 (-1.31%)

CODX Co-Diagnostics
$22.19 /

-1.2 (-5.13%)

AUPH Aurinia Pharmaceuticals
$17.39 /

-0.19 (-1.08%)

AMAT Applied Materials
$54.51 /

+2.98 (+5.78%)

ACB Aurora Cannabis
$6.61 /

+0.79 (+13.57%)

YTEN Yield10 Bioscience
$4.92 /

-0.02 (-0.40%)

TGTX TG Therapeutics
$19.90 /

-0.72 (-3.49%)

REGN Regeneron
$569.80 /

-7.58 (-1.31%)

FTCH Farfetch
$15.94 /

+0.35 (+2.25%)

DENN Denny's
$8.77 /

-0.035 (-0.40%)

CVET Covetrus
$11.25 /

+0.3 (+2.74%)

CODX Co-Diagnostics
$22.19 /

-1.2 (-5.13%)

AUPH Aurinia Pharmaceuticals
$17.39 /

-0.19 (-1.08%)

AMAT Applied Materials
$54.51 /

+2.98 (+5.78%)

ACB Aurora Cannabis
$6.61 /

+0.79 (+13.57%)

TGTX TG Therapeutics
$19.90 /

-0.72 (-3.49%)

REGN Regeneron
$569.80 /

-7.58 (-1.31%)

FTCH Farfetch
$15.94 /

+0.35 (+2.25%)

DENN Denny's
$8.77 /

-0.035 (-0.40%)

CODX Co-Diagnostics
$22.19 /

-1.2 (-5.13%)

AUPH Aurinia Pharmaceuticals
$17.39 /

-0.19 (-1.08%)

AMAT Applied Materials
$54.51 /

+2.98 (+5.78%)

ACB Aurora Cannabis
$6.61 /

+0.79 (+13.57%)

Earnings
Aurinia reports Q1 EPS (15c), consensus (15c) » 16:03
05/14/20
05/14
16:03
05/14/20
16:03
AUPH

Aurinia Pharmaceuticals

$17.44 /

-0.14 (-0.80%)

Reports Q1 revenue…

Reports Q1 revenue $30,000, consensus $50,000. "We are fortunate that the global COVID-19 pandemic has had minimal impact on Aurinia's operations, and we have maintained our timelines to ensure the filing of the voclosporin NDA by the end of the second quarter and hopefully obtain approval in early 2021," commented Peter Greenleaf, President and Chief Executive Officer of Aurinia. "Following the positive AURORA data reported last December we have strengthened the balance sheet, added world-class commercial expertise including the appointments of Timothy, Max, and Joe, and on-boarded a group of extraordinarily talented commercial leaders and additional staff." Greenleaf further stated, "With the establishment of our commercial hub in Maryland, we're building and preparing for the U.S. launch of voclosporin as the first FDA-approved treatment for lupus nephritis. In addition, the VOS development program remains on target, and we anticipate reporting out top-line results from the Phase 2/3 AUDREY dose-ranging trial of VOS during the fourth quarter of this year." Dr. Neil Solomons, Chief Medical Officer of Aurinia commented, "With respect to FSGS, our exploratory study has been open for an extended period and due to the continued difficulty identifying and enrolling primary FSGS patients, we've decided to adjust our approach. We are preparing to evaluate voclosporin in other proteinuric kidney diseases, while continuing to support patients who have participated in the FSGS exploratory study. As we work to incorporate these broader populations further updates will be available later this year."

ShowHide Related Items >><<
AUPH Aurinia Pharmaceuticals
$17.44 /

-0.14 (-0.80%)

AUPH Aurinia Pharmaceuticals
$17.44 /

-0.14 (-0.80%)

05/05/20 Cowen
Aurinia Pharmaceuticals initiated with an Outperform at Cowen
03/16/20 H.C. Wainwright
Aurinia's voclosporin could get FDA approval in 1Q21, says H.C. Wainwright
01/10/20 Jefferies
Aurinia Pharmaceuticals initiated with a Buy at Jefferies
12/16/19 H.C. Wainwright
Aurinia Pharmaceuticals price target raised to $32 from $25 at H.C. Wainwright
AUPH Aurinia Pharmaceuticals
$17.44 /

-0.14 (-0.80%)

AUPH Aurinia Pharmaceuticals
$17.44 /

-0.14 (-0.80%)

AUPH Aurinia Pharmaceuticals
$17.44 /

-0.14 (-0.80%)

AUPH Aurinia Pharmaceuticals
$17.44 /

-0.14 (-0.80%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.